Search - tctmd.com

Displaying 61 - 80 of 196

Sort: Relevancy | Date

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

Shelley Wood

March 01, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Opinion Editor's Corner

TCTMD 年十大热门新闻、博客和焦点

Shelley Wood

December 29, 2016

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Michael O'Riordan

November 08, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

The Great Absorb Debate: Is Absorb Ready To Be Used In Most Patients And Lesions? No Short-Term Data Is Borderline, Procedures Are More Costly And Complex, And Long-Term Data Is Scant Best To Wait!

Presenter: Stephen G. Ellis, Corrado Tamburino, Daniel I. Simon

October 31, 2016

Presentation TCT 2016

The Great Absorb Debate: Is Absorb Ready To Be Used In Most Patients And Lesions? Yes With Proper Technique And Planning, Nearly All PCI Patients Can Benefit From BVS!

Presenter: Stephen G. Ellis, Corrado Tamburino, Massimo Napodano

October 31, 2016

Presentation TCT 2016

Outcome Registries VII: IT-DISAPPEARS

Presenter: Stephen G. Ellis, Corrado Tamburino, Anna Sonia Petronio

October 31, 2016

Presentation TCT 2016

Outcome Registries VI: France ABSORB

Presenter: Stephen G. Ellis, Corrado Tamburino, Didier Carrié

October 31, 2016

Presentation TCT 2016

Outcome Registries V: New Insights From GHOST

Presenter: Stephen G. Ellis, Corrado Tamburino

October 31, 2016

Advertisement

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Live From Washington: ACC 2017, Day Two

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

TCTMD’s Top 10 Most Popular Stories for February 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

TCTMD’s Top 10 Most Popular News and Features for 2016

TCTMD 年十大热门新闻、博客和焦点

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

The Great Absorb Debate: Is Absorb Ready To Be Used In Most Patients And Lesions? No Short-Term Data Is Borderline, Procedures Are More Costly And Complex, And Long-Term Data Is Scant Best To Wait!

The Great Absorb Debate: Is Absorb Ready To Be Used In Most Patients And Lesions? Yes With Proper Technique And Planning, Nearly All PCI Patients Can Benefit From BVS!

Outcome Registries VII: IT-DISAPPEARS

Outcome Registries VI: France ABSORB

Outcome Registries V: New Insights From GHOST

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content